GlassScriptPhysician profile
Deronna Moore
NPI 1487067534
$652.87
in general payments reported to CMS, 2019-2025
15 companies · $297 in 2025
The $297 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $27.32 · 2022: $88.16 · 2023: $54.40 · 2024: $186 · 2025: $297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $537.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $537.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $116.05 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $109.28 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.56 | 2024-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $45.85 | 2022-2025 | Trelegy Ellipta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $43.33 | 2022-2025 | Caplyta |
| Axsome Therapeutics, INC. | $41.66 | 2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $36.57 | 2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $32.70 | 2021-2022 | |
| Lilly USA, LLC | $31.38 | 2023-2024 | Mounjaro |
| Amgen INC. | $28.11 | 2023-2025 | Otezla, Repatha, Otezla |
| Verona Pharma, INC. | $28.07 | 2025 | Ohtuvayre |
| Pfizer INC. | $24.09 | 2024 | |
| Corcept Therapeutics | $22.70 | 2025 | Korlym |
| Vanda Pharmaceuticals INC. | $17.20 | 2024 | Hetlioz, Fanapt |
| Genentech USA, INC. | $14.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deronna Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.